FDA requires monitoring of long-term clinical outcomes for robotic surgery in breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA issued a safety communication Aug. 20 that included new recommendations for IRBs and investigators studying robotically-assisted surgical devices for use in mastectomy procedures or in the prevention or treatment of breast cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Can you spare 10 minutes to complete a survey?

Your feedback is really important—you're helping us shape our coverage priorities and services to better serve you, our readers.

Login